Principal Financial Group Increases Stake in Alnylam Pharmaceuticals,
November 30, 2023
🌥️Trending News
Principal Financial Group Inc. has recently increased its stake in Alnylam Pharmaceuticals ($NASDAQ:ALNY), Inc., indicating a strong vote of confidence in the company. Alnylam Pharmaceuticals is a biopharmaceutical company with a mission to discover, develop, and deliver transformational medicines for the treatment of serious diseases. The company is focused on RNAi therapeutics to target genetic drivers of disease, which are based on Nobel Prize-winning technology.
Alnylam Pharmaceuticals has a robust pipeline of investigational drugs, and their lead product, Onpattro, is currently the first and only approved RNAi therapeutic in the U.S. The company also has products in clinical trials for Hemophilia A, Familial Chylomicronemia Syndrome, and ATTR Amyloidosis. Alnylam Pharmaceuticals is poised to make significant advances in the treatment of many serious diseases and Principal Financial Group’s increased stake signals their confidence in the company’s future.
Price History
Principal Financial Group Inc. recently announced that it had increased its stake in Alnylam Pharmaceuticals, Inc. On Monday, Alnylam Pharmaceuticals stock opened at $162.4 and closed at $159.2 for the day, a decrease of 2.3% from its prior closing price of $162.9. This recent decision by Principal Financial Group Inc. has sparked optimism regarding Alnylam Pharmaceuticals and its products in the market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Alnylam Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 1.72k | -509.87 | -24.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Alnylam Pharmaceuticals. More…
| Operations | Investing | Financing |
| 1.97 | -235.6 | 196.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Alnylam Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.84k | 4k | -1.32 |
Key Ratios Snapshot
Some of the financial key ratios for Alnylam Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 62.6% | – | -22.2% |
| FCF Margin | ROE | ROA |
| -3.9% | 83.4% | -6.2% |
Analysis
As an investor, a thorough analysis of ALNYLAM PHARMACEUTICALS’s financials is important when deciding whether or not to invest in the company. With GoodWhale’s Star Chart, we can quickly assess the company’s overall financial health and what type of investors may be interested. Our Star Chart indicates that ALNYLAM PHARMACEUTICALS has a low health score of 2/10 with regard to its cashflows and debt, making it less likely to sustain future operations in times of crisis. Although ALNYLAM PHARMACEUTICALS is strong in growth, medium in asset and weak in dividend, profitability, it’s classified as a ‘cheetah’– a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. Given ALNYLAM PHARMACEUTICALS’s low financial health score and ‘cheetah’ classification, investors should be aware of the company’s risk factors and potential volatility when considering investing. Investors who are comfortable with taking on higher risk for potentially greater returns may be interested in ALNYLAM PHARMACEUTICALS. More…
Peers
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s competitors include Regeneron Pharmaceuticals Inc, Intellia Therapeutics Inc, and Novartis AG.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
As of 2022, Regeneron Pharmaceuticals Inc has a market cap of 79.02B and a Return on Equity of 19.7%. The company is a biotech company that focuses on the discovery, development, and commercialization of medicines for the treatment of serious medical conditions.
– Intellia Therapeutics Inc ($NASDAQ:NTLA)
Intellia Therapeutics is a gene-editing company that focuses on developing therapeutics to treat serious diseases. The company has a market cap of $3.96 billion as of 2022 and a return on equity of -26.91%. Intellia’s gene-editing technology is based on CRISPR-Cas9, which is a naturally occurring bacterial system that can be used to target and edit specific genes. The company’s pipelines include programs for sickle cell disease, beta thalassemia, Huntington’s disease, and transthyretin amyloidosis.
– Novartis AG ($LTS:0QM7)
Novartis AG is a global pharmaceutical company with a market cap of 169.13B as of 2022. It has a Return on Equity of 24.65%. The company focuses on the discovery, development, and commercialization of healthcare products. Novartis’s products include over-the-counter and prescription drugs, vaccines, and diagnostic tools. The company has operations in over 140 countries and its products are sold in 180 countries.
Summary
Principal Financial Group Inc. has recently taken a stake in Alnylam Pharmaceuticals, Inc., signaling a bullish outlook for the company. Alnylam is a biotechnology company focused on discovering, developing and commercializing innovative RNA interference (RNAi) therapeutics. Analysts have noted that Alnylam has a strong product pipeline and a deep drug-discovery platform, making it an attractive investment for the long-term. Several of its drugs are already in clinical trials, with some showing impressive results.
Additionally, Alnylam has been able to obtain significant funding from major pharmaceutical companies, allowing it to expand its operations rapidly. This provides investors with confidence that the company has the necessary resources to progress through its drug development process. Financial performance and stock trends also suggest that Alnylam could be a lucrative investment opportunity in the near future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
